Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice

Fatima Cardoso, Marco Colleoni, Angelo Di Leo, Giulio Francia, Alessandra Gennari, Joseph Gligorov, Antonio Llombart

Research output: Contribution to journalArticle

Abstract

Metastatic breast cancer (MBC) is quite sensitive to chemotherapy, with patients often benefiting from multiple lines of treatment. Continuation of chemotherapy until disease progression, if tolerable, prolongs disease control and improves patient outcomes. Compared to combination regimens, sequential single-agent chemotherapy provides similar efficacy and improved tolerability and may represent the preferred option for most patients. Numerous agents are available, but there are few data to advise optimal sequencing. Oral chemotherapeutic agents, including capecitabine and vinorelbine, have demonstrated significant efficacy in patients with MBC. These drugs prolong disease control with good tolerability, especially when used as single agents. In addition, oral chemotherapy reduces the time and cost associated with treatment and usually is preferred by patients if compared with intravenous delivery. Metronomic administration of oral chemotherapy also represents a promising therapeutic approach for select patients with MBC, inhibiting tumor progression through multiple mechanisms of action. Ongoing clinical trials are exploring metronomic regimens as a strategy to prolong disease control with favorable tolerability. Key data on the role for oral chemotherapy in the therapeutic landscape for MBC will be reviewed and accompanied by expert perspectives on important considerations for the integration of oral chemotherapeutic agents into the treatment of patients with MBC.

Original languageEnglish
Pages (from-to)S1-S10
JournalCancer Treatment Communications
Volume6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Breast Neoplasms
Drug Therapy
Metronomic Administration
Therapeutics
Disease Progression
Clinical Trials
Costs and Cost Analysis
Pharmaceutical Preparations
Neoplasms

Keywords

  • Breast cancer
  • Capecitabine
  • Chemotherapy
  • Metastatic
  • Metronomic drug administration
  • Oral drug administration
  • Patient selection
  • Quality of life
  • Safety
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology

Cite this

Oral chemotherapy in advanced breast cancer : expert perspectives on its role in clinical practice. / Cardoso, Fatima; Colleoni, Marco; Di Leo, Angelo; Francia, Giulio; Gennari, Alessandra; Gligorov, Joseph; Llombart, Antonio.

In: Cancer Treatment Communications, Vol. 6, 01.06.2016, p. S1-S10.

Research output: Contribution to journalArticle

Cardoso, Fatima ; Colleoni, Marco ; Di Leo, Angelo ; Francia, Giulio ; Gennari, Alessandra ; Gligorov, Joseph ; Llombart, Antonio. / Oral chemotherapy in advanced breast cancer : expert perspectives on its role in clinical practice. In: Cancer Treatment Communications. 2016 ; Vol. 6. pp. S1-S10.
@article{eddee5f1a2bc48d59262b54cb3af844a,
title = "Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice",
abstract = "Metastatic breast cancer (MBC) is quite sensitive to chemotherapy, with patients often benefiting from multiple lines of treatment. Continuation of chemotherapy until disease progression, if tolerable, prolongs disease control and improves patient outcomes. Compared to combination regimens, sequential single-agent chemotherapy provides similar efficacy and improved tolerability and may represent the preferred option for most patients. Numerous agents are available, but there are few data to advise optimal sequencing. Oral chemotherapeutic agents, including capecitabine and vinorelbine, have demonstrated significant efficacy in patients with MBC. These drugs prolong disease control with good tolerability, especially when used as single agents. In addition, oral chemotherapy reduces the time and cost associated with treatment and usually is preferred by patients if compared with intravenous delivery. Metronomic administration of oral chemotherapy also represents a promising therapeutic approach for select patients with MBC, inhibiting tumor progression through multiple mechanisms of action. Ongoing clinical trials are exploring metronomic regimens as a strategy to prolong disease control with favorable tolerability. Key data on the role for oral chemotherapy in the therapeutic landscape for MBC will be reviewed and accompanied by expert perspectives on important considerations for the integration of oral chemotherapeutic agents into the treatment of patients with MBC.",
keywords = "Breast cancer, Capecitabine, Chemotherapy, Metastatic, Metronomic drug administration, Oral drug administration, Patient selection, Quality of life, Safety, Vinorelbine",
author = "Fatima Cardoso and Marco Colleoni and {Di Leo}, Angelo and Giulio Francia and Alessandra Gennari and Joseph Gligorov and Antonio Llombart",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/S2213-0896(16)06001-1",
language = "English",
volume = "6",
pages = "S1--S10",
journal = "Cancer Treatment Communications",
issn = "2213-0896",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Oral chemotherapy in advanced breast cancer

T2 - expert perspectives on its role in clinical practice

AU - Cardoso, Fatima

AU - Colleoni, Marco

AU - Di Leo, Angelo

AU - Francia, Giulio

AU - Gennari, Alessandra

AU - Gligorov, Joseph

AU - Llombart, Antonio

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Metastatic breast cancer (MBC) is quite sensitive to chemotherapy, with patients often benefiting from multiple lines of treatment. Continuation of chemotherapy until disease progression, if tolerable, prolongs disease control and improves patient outcomes. Compared to combination regimens, sequential single-agent chemotherapy provides similar efficacy and improved tolerability and may represent the preferred option for most patients. Numerous agents are available, but there are few data to advise optimal sequencing. Oral chemotherapeutic agents, including capecitabine and vinorelbine, have demonstrated significant efficacy in patients with MBC. These drugs prolong disease control with good tolerability, especially when used as single agents. In addition, oral chemotherapy reduces the time and cost associated with treatment and usually is preferred by patients if compared with intravenous delivery. Metronomic administration of oral chemotherapy also represents a promising therapeutic approach for select patients with MBC, inhibiting tumor progression through multiple mechanisms of action. Ongoing clinical trials are exploring metronomic regimens as a strategy to prolong disease control with favorable tolerability. Key data on the role for oral chemotherapy in the therapeutic landscape for MBC will be reviewed and accompanied by expert perspectives on important considerations for the integration of oral chemotherapeutic agents into the treatment of patients with MBC.

AB - Metastatic breast cancer (MBC) is quite sensitive to chemotherapy, with patients often benefiting from multiple lines of treatment. Continuation of chemotherapy until disease progression, if tolerable, prolongs disease control and improves patient outcomes. Compared to combination regimens, sequential single-agent chemotherapy provides similar efficacy and improved tolerability and may represent the preferred option for most patients. Numerous agents are available, but there are few data to advise optimal sequencing. Oral chemotherapeutic agents, including capecitabine and vinorelbine, have demonstrated significant efficacy in patients with MBC. These drugs prolong disease control with good tolerability, especially when used as single agents. In addition, oral chemotherapy reduces the time and cost associated with treatment and usually is preferred by patients if compared with intravenous delivery. Metronomic administration of oral chemotherapy also represents a promising therapeutic approach for select patients with MBC, inhibiting tumor progression through multiple mechanisms of action. Ongoing clinical trials are exploring metronomic regimens as a strategy to prolong disease control with favorable tolerability. Key data on the role for oral chemotherapy in the therapeutic landscape for MBC will be reviewed and accompanied by expert perspectives on important considerations for the integration of oral chemotherapeutic agents into the treatment of patients with MBC.

KW - Breast cancer

KW - Capecitabine

KW - Chemotherapy

KW - Metastatic

KW - Metronomic drug administration

KW - Oral drug administration

KW - Patient selection

KW - Quality of life

KW - Safety

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=84976532841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976532841&partnerID=8YFLogxK

U2 - 10.1016/S2213-0896(16)06001-1

DO - 10.1016/S2213-0896(16)06001-1

M3 - Article

AN - SCOPUS:84976532841

VL - 6

SP - S1-S10

JO - Cancer Treatment Communications

JF - Cancer Treatment Communications

SN - 2213-0896

ER -